HTG Introduces Multiplexed Mini-Microarray Solution
Complete the form below to unlock access to ALL audio articles.
HTG, Inc. has introduced the M3® Series, the multiplexed mini-microarray solution for biomarker discovery and gene profiling. The M3 series allows researchers to monitor the behavior of multiple genes in the same sample, simplifying experiments and lowering costs.
The platform is based on HTG’s qNPA ArrayPlate technology, which allows researchers to investigate a customized set of genes with greater precision than traditional microarrays.
The M3 Series consists of HTG’s qCustom™ ArrayPlate, qFix™ Arrays and two chemiluminescent imagers, the Omix™ II Imager, and Capella™ Imager, that are used in conjunction with the customizable multiplexed mini-microarrays. Mini-microarrays can be run in a customer’s lab or as a service at HTG. These custom arrays can be designed to detect any transcript.
In addition to the custom M3 arrays, HTG is introducing qSelect™ Custom Arrays, off-the-shelf M3 solutions, built from an expanding library of on-demand genes.
According to HTG, the M3 can enable researchers to perform multiple runs per sample, improving the statistical reliability of the data. The M3’s qNPA platform provides quantitative test results, enabling clients to compress drug discovery and development program timelines, increase program successes and reduce costs.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG’s platform is flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification.
